Merck & Co., Inc. stock (US58933Y1055): pharma giant doubles down on M&A as investors eye post-Keytruda era

Merck & Co., Inc. is ramping up acquisitions, deploying roughly $26 billion on deals from April 2025 to April 2026 as it prepares for Keytruda’s patent expiry. What this aggressive strategy could mean for revenues, risks and valuation now draws fresh attention from US and global investors.

Merck & Co., Inc. is back in the spotlight after data compiled by GuruFocus showed that the US pharmaceutical group deployed nearly $26 billion on mergers and acquisitions between April 2025 and April 2026, underlining an aggressive deal strategy ahead of the expected 2028 patent expiry of flagship cancer drug Keytruda, according to GuruFocus as of 05/14/2026.

As of: 15.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Merck & Co.
• Sector/industry: Pharmaceuticals, biotechnology
• Headquarters/country: Rahway, New Jersey, United States
• Core markets: Oncology, vaccines, hospital acute care, immunology
• Key revenue drivers: Keytruda cancer therapy, vaccines such as Gardasil, animal health products
• Home exchange/listing venue: New York Stock Exchange (ticker: MRK)
• Trading currency: US dollar (USD)

Merck & Co., Inc.: core business model

Merck & Co., Inc. operates as a global research-based pharmaceutical company with a focus on prescription medicines, vaccines and animal health products. Its business model is centered on discovering, developing, manufacturing and marketing innovative therapies for serious diseases. The company’s scale, long-term R&D investment and global commercial infrastructure position it among the largest healthcare groups in the world.

A major pillar of Merck’s model is oncology, where blockbuster immunotherapy Keytruda has become a standard of care in multiple cancer types. The drug, built on immune checkpoint inhibition, is approved in dozens of indications worldwide and generates a significant share of the group’s pharmaceutical revenue. Vaccines, particularly the human papillomavirus vaccine Gardasil, contribute another sizeable portion of sales, supported by ongoing public-health immunization programs.

Beyond human medicines, Merck derives revenue from its animal health business, which develops veterinary pharmaceuticals and vaccines. This segment serves livestock and companion animals and has become a strategic diversification pillar, offering somewhat different demand patterns compared with human health. The company monetizes its products through direct sales to healthcare providers, hospitals, government agencies and distributors, often using a mix of in-house salesforces and commercial partners.

To sustain its pipeline, Merck reinvests heavily in research and development, targeting areas such as oncology, infectious diseases, cardiometabolic conditions and immunology. Internal research is complemented by licensing agreements, collaborations and acquisitions, which provide access to external innovation. This combination of in-house science and external partnerships aims to feed a steady stream of candidates into clinical trials and, ultimately, commercial launches.

Pricing power plays an important role in Merck’s economics. Many of its therapies address high unmet medical need, which can justify premium pricing in markets such as the United States, although reimbursement negotiations and cost-containment efforts by payers create ongoing pressure. Geographic diversification across the US, Europe, Asia and emerging markets helps balance differing regulatory and pricing environments, while also exposing the company to currency fluctuations.

Main revenue and product drivers for Merck & Co., Inc.

Merck’s revenue profile has been dominated in recent years by Keytruda, which is used to treat several types of cancer and has steadily expanded its label through new clinical data and regulatory approvals. The product’s success has transformed the company’s earnings power but has also increased concentration risk, since a large portion of pharmaceutical revenue depends on a single molecule that faces patent expiry in the United States in 2028, as flagged by market observers in the recent M&A analysis from GuruFocus as of 05/14/2026.

Vaccines, especially Gardasil for the prevention of HPV-related cancers, represent the second major pillar. Demand is tied to national immunization schedules and awareness campaigns, and volumes can fluctuate with public-health priorities and funding cycles. The vaccines franchise benefits from high barriers to entry, given the manufacturing complexity and regulatory requirements, which can support relatively stable margins for established products.

Merck’s hospital acute care portfolio, which includes therapies for infectious diseases and critical care, adds another important revenue stream. These medicines are typically prescribed in inpatient settings and can see demand spikes during outbreaks or shifts in medical practice. The company also markets cardiometabolic and immunology therapies, although these areas currently contribute less to total revenue than oncology and vaccines.

The animal health division has grown into a meaningful contributor, selling pharmaceuticals and vaccines for both production animals and pets. Trends such as rising protein consumption in emerging markets and increased spending on companion-animal healthcare in developed countries support structural growth in this unit. Because animal health is less exposed to some of the reimbursement dynamics of human medicine, it can provide a degree of earnings diversification.

From a financial perspective, Merck’s reported valuation reflects these revenue drivers. According to market data on Robinhood, the company’s shares recently traded around the low-$110s, implying a market capitalization of roughly $280 billion and a price-to-earnings multiple near the low-30s, with a dividend yield of about 2.9%, as indicated by Robinhood as of 05/15/2026. These figures underscore investor expectations for continued cash generation from Keytruda and other franchises.

Why Merck is intensifying M&A ahead of Keytruda’s patent cliff

The recent report that Merck deployed nearly $26 billion on M&A transactions between April 2025 and April 2026 highlights how central acquisitions have become to its strategy. According to GuruFocus, the company has targeted oncology, immunology and central nervous system assets, seeking to build future growth pillars that could help offset eventual erosion of Keytruda revenue, as noted by GuruFocus as of 05/14/2026.

Across the broader pharmaceutical sector, deal-making has accelerated, with dozens of notable transactions announced in late 2025 and early 2026. Industry observers attribute this to a combination of factors: looming patent expiries on established blockbusters, substantial cash balances at big pharma companies and the desire to secure promising biotech pipelines before competition intensifies. Merck’s activity fits squarely within this trend, signaling that it intends to play an active role in reshaping its portfolio.

For Merck, the stakes are high. As Keytruda approaches its US loss of exclusivity, management faces the challenge of replacing a large revenue stream while preserving margins. Acquisitions can accelerate access to late-stage or commercial assets, but they come with integration execution risk, potential overpayment and the possibility that clinical or commercial performance falls short of expectations. The balance between de-risking the revenue base and maintaining capital discipline is closely watched by investors.

The company’s willingness to pursue sizeable deals suggests confidence in its balance sheet and cash generation capacity. Keytruda’s current cash flows, combined with other product lines and the animal health segment, provide firepower to fund transactions and sustain the dividend. At the same time, a valuation multiple in the low-30s on earnings, as referenced by recent market data, implies that equity investors are already pricing in a mix of growth prospects and risk, leaving limited room for missteps in large acquisitions.

This environment can create contrasting investor reactions. Some shareholders may welcome a proactive approach to building the post-Keytruda portfolio, interpreting the M&A push as a sign that Merck is leaning into its scale advantage. Others might worry about integration complexity or the potential for write-downs if acquired pipelines do not deliver. The coming years are therefore likely to see heightened scrutiny of each announced transaction and its strategic fit.

Industry trends and competitive position

Merck operates in a highly competitive global pharmaceutical landscape, where peers such as Bristol Myers Squibb, Pfizer and Johnson & Johnson also vie for leadership in oncology, immunology and vaccines. The sector has seen growing emphasis on combination therapies, biomarker-driven treatments and personalized medicine, particularly in cancer. Merck’s strength in immuno-oncology, anchored by Keytruda, has helped it secure a leading position in several tumor types.

At the same time, the regulatory and reimbursement climate remains demanding. Authorities in the United States and Europe are scrutinizing drug pricing and seeking value-based arrangements, which can influence launch strategies and long-term revenue trajectories. Global programs to expand access to vaccines and essential medicines create both opportunities and margin pressure. Merck’s scale and experience with large public-health contracts can be an advantage, but they also bring responsibility to demonstrate clinical and economic value.

On the innovation front, advances in modalities such as cell and gene therapies, RNA-based treatments and next-generation antibodies are reshaping the opportunity set. Merck’s pipeline and business-development efforts aim to tap into these trends, either through internal research or partnerships. Success will depend on navigating scientific, regulatory and manufacturing challenges while competing against specialized biotech firms and other large pharmaceutical companies pursuing similar targets.

Why Merck & Co., Inc. matters for US investors

For US-based investors, Merck represents one of the core large-cap healthcare names on the New York Stock Exchange, with deep liquidity and inclusion in major equity indices. Its performance can influence sector benchmarks and healthcare allocations in diversified portfolios. The company’s exposure to US healthcare spending, public insurance programs and private payers also ties its prospects closely to domestic policy developments.

Dividend payments, currently yielding close to 3% based on recent market quotations, make Merck relevant for income-oriented investors who seek established companies with recurring cash distributions. At the same time, the sizable R&D budget and deal pipeline appeal to those watching for long-term growth driven by scientific innovation. The combination of a defensive healthcare profile and specific product and pipeline risks gives the stock a distinct place in many US portfolios.

Conclusion

Merck & Co., Inc. is entering a pivotal strategic phase as it accelerates M&A activity to prepare for the eventual loss of exclusivity on Keytruda, its key oncology growth engine. Recent data pointing to roughly $26 billion of transactions over a 12?month period underscore management’s determination to broaden the portfolio in oncology, immunology and other therapeutic areas. At the same time, the company continues to rely on strong vaccine and animal health franchises, which provide diversification.

Investors are weighing the benefits of this proactive approach against the inherent risks of large-scale deal-making, including integration challenges and the possibility of clinical setbacks in acquired pipelines. Current valuation metrics, including a P/E multiple in the low-30s and a dividend yield near 2.9% based on recent prices, suggest the market is assigning meaningful value to Merck’s cash flows and future pipeline while remaining attentive to execution. How effectively the company converts its acquisition spending and R&D investments into sustainable post-Keytruda earnings will likely be a central narrative for the stock in the coming years.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.